Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185–229.

Article  CAS  Google Scholar 

Vandecruys E, Mondelaers V, De Wolf D, Benoit Y, Suys B. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood. J Cancer Surviv. 2012;6(1):95–101.

Article  Google Scholar 

Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66(4):309–25.

Article  Google Scholar 

Zhang Y, Zhu W, Ding C, Chen M, Su X, Dai W, et al. Nicorandil, a promising drug for the prevention of percutaneous coronary artery intervention-related myocardial injury and infarction in patients with stable coronary artery disease. Int J Cardiol. 2020;308:10.

Article  Google Scholar 

Xing Y, Liu C, Wang H, Zhang X, Wang Y, Yue X, et al. Protective effects of Nicorandil on cardiac function and left ventricular remodeling in a rat model of ischemic heart failure. Arch Med Res. 2018;49(8):583–7.

Article  CAS  Google Scholar 

Wang X, Pan J, Liu D, Zhang M, Li X, Tian J, et al. Nicorandil alleviates apoptosis in diabetic cardiomyopathy through PI3K/Akt pathway. J Cell Mol Med. 2019;23(8):5349–59.

Article  CAS  Google Scholar 

Khames A, Khalaf MM, Gad AM, Abd El-Raouf OM, Kandeil MA. Nicorandil combats doxorubicin-induced nephrotoxicity via amendment of TLR4/P38 MAPK/NFκ-B signaling pathway. Chem Biol Interact. 2019;311:108777.

Article  Google Scholar 

Quagliariello V, Vecchione R, Coppola C, Di Cicco C, De Capua A, Piscopo G, et al. Cardioprotective effects of nanoemulsions loaded with anti-inflammatory nutraceuticals against doxorubicin-induced cardiotoxicity. Nutrients. 2018;10(9):1304.

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8.

Article  CAS  Google Scholar 

Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–20.

Article  CAS  Google Scholar 

López-Fernández T, Martín García A, Santaballa Beltrán A, Montero Luis Á, García Sanz R, Mazón Ramos P, et al. Cardio-onco-hematology in clinical practice. Position Paper and Recommendations. Revista espanola de cardiologia (English ed). 2017;70(6):474–86.

Google Scholar 

Ewer MS, Ali MK, Mackay B, Wallace S, Valdivieso M, Legha SS, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol : Off J Am Soc Clin Oncol. 1984;2(2):112–7.

Article  CAS  Google Scholar 

Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36(2):517–22.

Article  CAS  Google Scholar 

Naresh NK, Misener S, Zhang Z, Yang C, Ruh A, Bertolino N, et al. Cardiac MRI myocardial functional and tissue Ccharacterization detects early cardiac dysfunction in a mouse model of chemotherapy-induced cardiotoxicity. NMR Biomed. 2020;33(9):e4327.

Mawad W, Mertens L, Pagano JJ, Riesenkampff E, Reichert MJE, Mital S, et al. Effect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors. Eur Heart J Cardiovasc Imaging. 2020;22(4):435–42.

Lambert J, Lamacie M, Thampinathan B, Altaha MA, Esmaeilzadeh M, Nolan M, et al. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity. Heart. 2020;106(11):817–23.

Article  CAS  Google Scholar 

Hong YJ, Park HS, Park JK, Han K, Park CH, Kim TK, et al. Early detection and serial monitoring of anthracycline-induced cardiotoxicity using T1-mapping cardiac magnetic resonance imaging: an animal study. Sci Rep. 2017;7(1):2663.

Article  Google Scholar 

Farhad H, Staziaki PV, Addison D, Coelho-Filho OR, Shah RV, Mitchell RN, et al. Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circ Cardiovasc Imaging. 2016;9(12):e003584.

Galán-Arriola C, Lobo M, Vílchez-Tschischke JP, López GJ, de Molina-Iracheta A, Pérez-Martínez C, et al. Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol. 2019;73(7):779–91.

Article  Google Scholar 

Chang WT, Feng YH, Kuo YH, Chen WY, Wu HC, Huang CT, et al. Layer-specific distribution of myocardial deformation from anthracycline-induced cardiotoxicity in patients with breast cancer-from bedside to bench. Int J Cardiol. 2020;311:64–70.

Article  Google Scholar 

Chakouri N, Farah C, Matecki S, Amedro P, Vincenti M, Saumet L, et al. Screening for in-vivo regional contractile defaults to predict the delayed doxorubicin cardiotoxicity in juvenile rat. Theranostics. 2020;10(18):8130–42.

Article  CAS  Google Scholar 

Zhang Y, Ma C, Liu C, Wei F. Luteolin attenuates doxorubicin-induced cardiotoxicity by modulating the PHLPP1/AKT/Bcl-2 signalling pathway. PeerJ. 2020;8:e8845.

Article  Google Scholar 

Liu Q, Yao JY, Qian C, Chen R, Li XY, Liu SW, et al. Effects of propofol on ischemia-induced ventricular arrhythmias and mitochondrial ATP-sensitive potassium channels. Acta Pharmacol Sin. 2012;33(12):1495–501.

Article  CAS  Google Scholar 

Narasimhan G, Carrillo ED, Hernández A, García MC, Sánchez JA. Protective action of Diazoxide on isoproterenol-induced hypertrophy is mediated by reduction in MicroRNA-132 expression. J Cardiovasc Pharmacol. 2018;72(5):222–30.

Article  CAS  Google Scholar 

Hole LD, Larsen TH, Fossan KO, Limé F, Schjøtt J. Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat. BMC Pharmacol Toxicol. 2014;15:28.

Article  Google Scholar 

Zhu J, Chen Y, Xu Z, Wang S, Wang L, Liu X, et al. Non-invasive assessment of early and acute myocarditis in a rat model using cardiac magnetic resonance tissue tracking analysis of myocardial strain. Quantitative Imaging Med Surg. 2020;10(11):2157–67.

Article  Google Scholar 

Ammirati E, Moroni F, Sormani P, Peritore A, Milazzo A, Quattrocchi G, et al. Quantitative changes in late gadolinium enhancement at cardiac magnetic resonance in the early phase of acute myocarditis. Int J Cardiol. 2017;231:216–21.

Article  Google Scholar 

Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the use of anthracyclines for breast cancer. J Clin Oncol. 2012;30(18):2232–9.

Article  CAS  Google Scholar 

Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, et al. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. Br J Haematol. 2015;170(1):85–95.

Article  CAS  Google Scholar 

Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017;70(20):2536–51.

Article  Google Scholar 

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017;19(1):9–42.

Article  Google Scholar 

Hirohata A, Yamamoto K, Hirose E, Kobayashi Y, Takafuji H, Sano F, et al. Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pectoris: a randomised study. EuroIntervention. 2014;9(9):1050–6.

Article  Google Scholar 

Zhang X, Yu Q, Yao X, Liu G, Li J, Du L. Effects of Nicorandil on all-cause mortality and cardiac events in CAD patients receiving PCI. Int Heart J. 2019;60(4):886–98.

Article  CAS  Google Scholar 

He WK, Su Q, Liang JB, Wang XT, Sun YH, Li L. Nicorandil pretreatment inhibits myocardial apoptosis and improves cardiac function after coronary microembolization in rats. J Geriatric Cardiol: JGC. 2018;15(9):591–7.

CAS  Google Scholar 

Zhao AP, Dong YF, Liu W, Gu J, Sun XL. Nicorandil inhibits inflammasome activation and toll-like receptor-4 signal transduction to protect against oxygen-glucose deprivation-induced inflammation in BV-2 cells. CNS Neurosci Ther. 2014;20(2):147–53.

Article  CAS  Google Scholar 

Raveaud S, Verdetti J, Faury G. Nicorandil protects ATP-sensitive potassium channels against oxidation-induced dysfunction in cardiomyocytes of aging rats. Biogerontology. 2009;10(5):537–47.

Article  CAS  Google Scholar 

Hu K, Wang X, Hu H, Xu Z, Zhang J, An G, et al. Intracoronary application of nicorandil regulates the inflammatory response induced by percutaneous coronary intervention. J Cell Mol Med. 2020;24(8):4863–70.

Article  CAS  Google Scholar 

Su Q, Lv X, Sun Y, Ye Z, Kong B, Qin Z. Role of TLR4/MyD88/NF-κB signaling pathway in coronary microembolization-induced myocardial injury prevented and treated with nicorandil. Biomed Pharmacother. 2018;106:776–84.

Article  CAS  Google Scholar 

Asensio-López MC, Soler F, Pascual-Figal D, Fernández-Belda F, Lax A. Doxorubicin-induced oxidative stress: the protective effect of nicorandil on HL-1 cardiomyocytes. PLoS One. 2017;12(2):e0172803.

Article  Google Scholar 

Abdel-Raheem IT, Taye A, Abouzied MM. Cardioprotective effects of nicorandil, a mitochondrial potassium channel opener against doxorubicin-induced cardiotoxicity in rats. Basic Clin Pharmacol Toxicol. 2013;113(3):158–66.

Article  CAS  Google Scholar 

Ahmed LA, El-Maraghy SA. Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection. Biochem Pharmacol. 2013;86(9):1301–10.

Article  CAS  Google Scholar 

Bosman M, Favere K, Neutel CHG, Jacobs G, De Meyer GRY, Martinet W, et al. Doxorubicin induces arterial stiffness: a comprehensive in vivo and ex vivo evaluation of vascular toxicity in mice. Toxicol Lett. 2021;346:23–33.

Article  CAS  Google Scholar 

Drafts BC, Twomley KM, D'Agostino R Jr, Lawrence J, Avis N, Ellis LR, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. J Am Coll Cardiol Img. 2013;6(8):877–85.

Article  Google Scholar 

Galán-Arriola C, Villena-Gutiérrez R, Higuero-Verdejo MI, Díaz-Rengifo IA, Pizarro G, López GJ, et al. Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity. Cardiovasc Res. 2021;117(4):1132–43.

Article  Google Scholar 

Mele D, Tocchetti CG, Pagliaro P, Madonna R, Novo G, Pepe A, et al. Pathophysiology of anthracycline cardiotoxicity. J Cardiovasc Med (Hagerstown, Md). 2016;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e3–e11.

Wu Q, Li W, Zhao J, Sun W, Yang Q, Chen C, et al. Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation. Biomed Pharmacother. 2021;137:111308.

Galán-Arriola C, Villena-Gutiérrez R, Higuero-Verdejo MI, Díaz-Rengifo IA, Pizarro G, López GJ, et al. Remote ischemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity. Cardiovasc Res. 2021;117(4):1132–43.

Wang Z, Wang M, Liu J, Ye J, Jiang H, Xu Y, et al. Inhibition of TRPA1 attenuates doxorubicin-induced acute cardiotoxicity by suppressing oxidative stress, the inflammatory response, and endoplasmic reticulum stress. Oxidative Med Cell Longev. 2018;2018:5179468.

Article  Google Scholar 

Li X, Geng J, Zhao J, Ni Q, Zhao C, Zheng Y, et al. Trimethylamine N-oxide exacerbates cardiac fibrosis via a